IP Library Granted Patent US 8,288,160
Granted Patent B2
US 8,288,160 · App. 12/911,292 · Granted Oct 16, 2012

Activation induced deaminase (AID)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,288,160
App. No.
12/911,292
Granted
Oct 16, 2012
Kind
B2
Abstract

The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide.

Claims (14)

1. An in vitro method for preparing a mutant immunoglobulin, which method comprises expressing in vitro in a eukaryotic cell a transgene comprising a nucleic acid encoding an immunoglobulin having a functional activity, wherein (i) the eukaryotic cell expresses AID mutation activity, (ii) expression of AID mutation activity in the eukaryotic cell induces a mutation in the nucleic acid encoding the immunoglobulin, and (iii) expression of the mutated nucleic acid produces a mutant immunoglobulin having a modulated functional activity as compared to the immunoglobulin prior to mutation.

2. The method of claim 1 , wherein the transgene comprising the nucleic acid encoding the immunoglobulin is in an expression vector.

3. The method of claim 2 , wherein the expression vector comprises an inducible promoter.

4. The method of claim 1 , wherein the transgene is chromosomally integrated into the genome of the eukaryotic cell.

5. The method of claim 4 , wherein the transgene became chromosomally integrated into the genome of the eukaryotic cell by homologous recombination.

6. The method of claim 2 , wherein the expression vector further comprises control sequences which direct hypermutation in the nucleic acid encoding the immunoglobulin.

7. The method of claim 1 , wherein AID mutation activity is mediated by an AID homolog selected from the group consisting of Apobec-1, Apobec3C, and Apobec3G.

8. The method of claim 1 , which is successively repeated.

9. The method of claim 1 , wherein AID mutation activity is transiently expressed in the eukaryotic cell.

10. The method of claim 1 , wherein AID mutation activity is stably expressed in the eukaryotic cell.

11. The method of claim 1 , which further comprises using binding to magnetic beads to determine whether the eukaryotic cell produces a mutant immunoglobulin having a modulated functional activity as compared to the immunoglobulin prior to mutation.

12. The method of claim 1 , which further comprises using affinity chromatography to determine whether the eukaryotic cell produces a mutant immunoglobulin having a modulated functional activity as compared to the immunoglobulin prior to mutation.

13. The method of claim 1 , wherein the functional activity is binding affinity for a ligand.

14. The method of claim 13 , wherein the ligand is an antigen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2018
From: MEDICAL RESEARCH COUNCIL
To: UNITED KINGDOM RESEARCH AND INNOVATION
Reel/Frame 046469/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2012
From: PETERSEN-MAHRT, SVEND K.; HARRIS, REUBEN; NEUBERGER, MICHAEL S.; BEALE, RUPERT CHRISTOPHER LANDSDOWNE
To: MEDICAL RESEARCH COUNCIL
Reel/Frame 029487/0766 →